Streetbeat News

Analyst Ratings

OXM

Top Wall Street forecasters have updated their expectations for Oxford Industries (NYSE:OXM) ahead of its Q1 fiscal 2024 earnings release. Analysts predict earnings of $2.69 per share, down from $3.78 a year ago, and revenue of $405.61 million. The company previously reported weak Q4 results and issued soft Q1 guidance. Recent analyst ratings include a Market Perform from Telsey Advisory Group, a downgrade to Sell from Citigroup, and Neutral ratings from UBS and BTIG.

Portfolio Pulse from Avi Kapoor

June 11, 2024 | 12:43 pm

GNFT

HC Wainwright & Co. analyst Ed Arce maintains a Buy rating on Genfit (NASDAQ:GNFT) and raises the price target from $11 to $13.

Portfolio Pulse from Benzinga Newsdesk

June 11, 2024 | 12:43 pm

GOOGL

Evercore ISI Group analyst Mark Mahaney maintains an Outperform rating on Alphabet (NASDAQ:GOOGL) and raises the price target from $220 to $225.

Portfolio Pulse from Benzinga Newsdesk

June 11, 2024 | 12:42 pm

SAGE

Needham analyst Ami Fadia has reiterated a Hold rating on Sage Therapeutics (NASDAQ:SAGE).

Portfolio Pulse from Benzinga Newsdesk

June 11, 2024 | 12:40 pm

SAGE

Baird analyst Joel Beatty maintains a Neutral rating on Sage Therapeutics (NASDAQ:SAGE) and keeps the price target at $15.

Portfolio Pulse from Benzinga Newsdesk

June 11, 2024 | 12:39 pm

BWMX

Small Cap Consumer Research analyst Eric Beder has reiterated a Buy rating on Betterware de Mexico SAPI (NYSE:BWMX) and maintained a price target of $22.5.

Portfolio Pulse from Benzinga Newsdesk

June 11, 2024 | 12:39 pm

CMA

Stephens & Co. analyst Terry McEvoy has reiterated an Overweight rating on Comerica (NYSE:CMA) and maintained a $64 price target.

Portfolio Pulse from Benzinga Newsdesk

June 11, 2024 | 12:35 pm

FITB

Stephens & Co. analyst Terry McEvoy has reiterated an Equal-Weight rating on Fifth Third Bancorp (NASDAQ:FITB) and maintained a $41 price target.

Portfolio Pulse from Benzinga Newsdesk

June 11, 2024 | 12:31 pm

ELV

Stephens & Co. analyst Scott Fidel has reiterated an Overweight rating on Elevance Health (NYSE:ELV) and maintained a price target of $615.

Portfolio Pulse from Benzinga Newsdesk

June 11, 2024 | 12:30 pm

CRBP

RBC Capital analyst Brian Abrahams maintains an Outperform rating on Corbus Pharmaceuticals (NASDAQ:CRBP) and raises the price target from $77 to $82.

Portfolio Pulse from Benzinga Newsdesk

June 11, 2024 | 12:17 pm